Related Experiment Video
Updated: May 27, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent
Nazia Chaudhary1, Bhagya Shree Choudhary1,2, Anusha Shivashankar1
1Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India.
Abstract:
Triple-Negative Breast Cancer (TNBC) is the most aggressive type of breast malignancy, with chemotherapy as the only mainstay treatment. TNBC patients have the worst prognoses as a large fraction of them do not achieve complete pathological response post-treatment and develop drug-resistant residual disease. Molecular mechanisms that trigger proliferation in drug-resistant chemo-residual TNBC cells are poorly understood due to the lack of investigations using clinically relevant cellular models. In this study, we have established TNBC subtype-specific cellular models of proliferating drug-tolerant persister (PDTP) cells using different classes of chemotherapeutic agents that recapitulate clinical residual disease with molecular heterogeneity. Analysis of total phospho-tyrosine signals in TNBC PDTPs showed an enhanced phospho-tyrosine content compared to the parental cells (PC). Interestingly, using mass-spectrometry analysis, we identified a dramatic decrease in epidermal growth factor receptor (EGFR) expression in the PDTPs, while the presence of hyper-activated tyrosine phosphorylation of EGFR compared to PC. Further, we show that EGFR has enhanced lysosomal trafficking in PDTPs with a concomitant increase in N-Myc Downstream Regulated-1 (NDRG1) expression that co-localizes with EGFR to mediate receptor degradation. More surprisingly, we found that reduced protein levels of EGFR are coupled with a robust increase in Src family kinases, including Lyn and Fyn kinases, that creates a hyper-phosphorylation state of EGFR-Src tyrosine kinases axis in PDTPs and mediates downstream over-activation of STAT3, AKT and MAP kinases. Moreover, paclitaxel-derived PDTPs show increased sensitivity to EGFR TKI Gefitinib and its combination with paclitaxel selectively induced cell death in Paclitaxel-derived PDTP (PDTP-P) TNBC cells and 3D spheroids by strongly downregulating phosphorylation of EGFR-Src with concomitant downregulation of Lyn and Fyn tyrosine kinases. Collectively, this study identifies a unique hyper-phosphorylation cellular state of TNBC PDTPs established by switching of EGFR-Src family tyrosine kinases, creating a vulnerability to EGFR TKI.
Insights
Triple-Negative Breast Cancer (TNBC) cells develop drug resistance. This study reveals a hyper-phosphorylation state in resistant TNBC cells, involving EGFR and Src kinases, creating a vulnerability to EGFR inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Triple-Negative Breast Cancer (TNBC) is aggressive, with limited treatment options and poor outcomes.
- Chemotherapy resistance and residual disease are major challenges in TNBC management.
- Molecular mechanisms driving proliferation in chemo-resistant TNBC cells remain poorly understood.
Purpose of the Study:
- To establish clinically relevant cellular models of chemo-resistant TNBC.
- To investigate the molecular mechanisms of proliferation in drug-tolerant persister (PDTP) cells.
- To identify potential therapeutic vulnerabilities in residual TNBC.
Main Methods:
- Established TNBC subtype-specific PDTP cellular models.
- Analyzed phospho-tyrosine signaling using mass spectrometry.
- Investigated protein expression, localization, and kinase activity (EGFR, Src family kinases, NDRG1, STAT3, AKT, MAP kinases).
- Assessed sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in combination with chemotherapy.
Main Results:
- TNBC PDTPs exhibit enhanced phospho-tyrosine content compared to parental cells.
- EGFR expression is decreased but hyper-phosphorylated in PDTPs.
- Increased lysosomal trafficking of EGFR mediated by NDRG1 was observed.
- A hyper-activated EGFR-Src kinase axis was identified, leading to downstream signaling over-activation.
- Paclitaxel-derived PDTPs showed sensitivity to Gefitinib, a EGFR TKI.
Conclusions:
- TNBC PDTPs develop a unique hyper-phosphorylation state driven by an EGFR-Src tyrosine kinase switch.
- This altered signaling creates a vulnerability exploitable by EGFR TKIs.
- Targeting the EGFR-Src axis offers a potential therapeutic strategy for chemo-resistant TNBC.
More Related Videos
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Related Concept Videos
Receptor Tyrosine Kinases
Mitogens and the Cell Cycle
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Ras Gene
Ras is a...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: